Table 9.
Polyunsaturated fatty acids (PUFA) content in the plasma FFA fraction (nmol/mL of plasma) in the control (standard diet) and high-fat diet (HFD) groups after two-week cannabidiol (CBD) treatment.
| Fatty Acid | Control | CBD | HFD | HFD + CBD |
|---|---|---|---|---|
| 18:2n6c | 55.06 ± 12.31 | 83.88 ± 23.49 a | 92.76 ± 25.91 a | 147.53 ± 40.28 a,b |
| 20:4n6 | 8.16 ± 1.68 | 15.36 ± 2.17 a | 16.37 ± 4.24 a | 17.34 ± 4.88 a |
| 18:3n3 | 6.39 ± 1.75 | 9.18 ± 2.54 a | 7.48 ± 1.73 | 12.50 ± 3.72 a,b |
| 20:5n3 | 0.40 ± 0.08 | 0.49 ± 0.13 a | 0.23 ± 0.05 a | 0.29 ± 0.08 a,b |
| 22:6n3 | 2.14 ± 0.58 | 4.30 ± 1.16 a | 2.82 ± 0.67 a | 3.53 ± 1.28 a,b |
| n-6 PUFAs | 63.22 ± 13.49 | 100.93 ± 26.71 a | 109.13 ± 28.51 a | 157.30 ± 40.34 a,b |
| n-3 PUFAs | 8.93 ± 2.35 | 14.49 ± 3.78 a | 10.14 ± 2.58 | 16.32 ± 4.81 a,b |
The data are expressed as mean values ± SD, n = 10 in each group. a p < 0.05 indicates a significant difference: the control group vs. the examined group; b p < 0.05 indicates a significant difference: HFD vs. HFD + CBD; 18:2n6c (linoleic acid, LA); 20:4n6 (arachidonic acid, AA); 18:3n3 (α-linolenic acid, ALA); 20:5n3 (eicosapentaenoic acid, EPA); 22:6n3 (docosahexaenoic acid, DHA).